As Trump 2.0 continues its assault on federally-funded research, a new study highlights what's at stake

John Carroll on why a new JAMA Oncology study — showing the NCI fills gaps industry won't touch, from pediatric cancers to dose de-escalation — matters as the Trump administration presses ahead with deep cuts to federal cancer research funding.